Key result
Pharmacogenetics in cardiovascular disease is on the verge of clinical application, with recent studies on drug-gene interactions leading to adaptations of FDA recommendations.
Systematic Review
This systematic review summarizes current knowledge on pharmacogenetics for major cardiovascular drug classes, highlighting its potential for clinical application to optimize efficacy and minimize adverse reactions.
Supports cautious adoption of pharmacogenetic guidance for CV drugs; extends evidence synthesis amid FDA updates.
Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the greatest potential of efficacy and smallest risk of adverse drug reactions. Many studies focusing on drug-gene interactions have been published in recent years, some of which led to adaptation of FDA recommendations, indicating that we are on the verge of the clinical application of genetic information in drug therapy. This systematic review provides a comprehensive overview of the current knowledge on pharmacogenetics of all major drug classes currently used in the treatment of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Verschuren et al. (2011) conducted a systematic review in Cardiovascular disease. Pharmacogenetics was evaluated. Pharmacogenetics in cardiovascular disease is on the verge of clinical application, with recent studies on drug-gene interactions leading to adaptations of FDA recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: